Hydrocil Instant
psyllium
Pharmacologic class: Psyllium colloid
Therapeutic class: Bulk-forming laxative
Pregnancy risk category B
Action
Stimulates lining of colon, increasing peristalsis and water absorption of stool and promoting evacuation
Availability
Chewable pieces: 1.7 g/piece, 3.4 g/piece
Granules: 2.5 g/tsp, 4.03 g/tsp
Powder: 3.3 g/tsp, 3.4 g/tsp, 3.5 g/tsp, 4.94 g/tsp
Powder (effervescent): 3.4 g/packet, 3.7 g/packet
Wafers: 3.4 g/2 wafers
Indications and dosages
➣ Chronic constipation; ulcerative colitis; irritable bowel syndrome
Adults and children ages 12 and older: 30 g daily in divided doses of 2.5 to 7.5 g/dose P.O. in 8 oz of water or juice
Contraindications
• Hypersensitivity to drug
• Intestinal obstruction
• Abdominal pain or other appendicitis symptoms
• Fecal impaction
Precautions
Use cautiously in:
• phenylketonuria
• pregnant patients.
Administration
• Mix powder with 8 oz of cold liquid (such as orange juice) to mask taste.
• Give diluted drug immediately after mixing, before it congeals. Follow with another glass of fluid.
Adverse reactions
GI: nausea; vomiting; diarrhea (with excessive use); abdominal cramps with severe constipation; anorexia; esophageal, gastric, small-intestine, or rectal obstruction (with dry form)
Respiratory: asthma (rare)
Other: severe allergic reactions including anaphylaxis
Interactions
None significant
Patient monitoring
• Monitor patient's bowel movements.
• Check for signs and symptoms of severe (but rare) allergic reactions, such as anaphylaxis and asthma.
Patient teaching
• Tell patient to dissolve in 8 oz of cold beverage and drink immediately, followed by another glass of liquid.
• Caution patient not to take without dissolving in liquid.
• Instruct patient to take after meals if drug decreases his appetite.
• Tell patient drug usually causes bowel movement within 12 to 24 hours but may take as long as 3 days.
See Instruct patient to immediately stop taking drug and notify prescriber if signs and symptoms of allergic reaction occur.
• Advise diabetic patient to use sugar-free drug form.
• Instruct patient with phenylketonuria to avoid forms containing phenylalanine.
• As appropriate, review all other significant and life-threatening adverse reactions.